Google
UNCY — UNICYCIVE THERAPEUTICS INC (Healthcare >> Biotechnology)
UNCY FAQ
What is UNCY's ROE?
UNICYCIVE THERAPEUTICS INC reports a Return on Equity (ROE) of -105.95%.
What is UNCY's dividend yield?
UNICYCIVE THERAPEUTICS INC offers a dividend yield of 0.00%.
What is UNCY's Deepscope Quality Score?
Deepscope rates UNCY's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy UNCY?
Deepscope's AI Timing Score for UNCY is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does UNCY belong to?
UNICYCIVE THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.27
Price
0.61
(9.16%)
Day Change
|
|
|---|
UNCY Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
ROE đang giảm đáng kể
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.27 |
| PBV / Sector |
4.90 / 4.71
|
| Earning Per Share | -1.57 |
| PE / Sector |
N/A / 17.58
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
5.69 M
GREAT
|
| Average 1W Daily Value |
6.00 M
|
| Yếu tố Kỹ thuật |
|
14% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
47% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-10 09:43:26 |
| Symbol | UNCY |
| Name | UNICYCIVE THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 26.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 184.76 / 8,889.42 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1975 West El Camino Real, Mountain View, CA, United States, 94040
Phone: 650 351 4495
Website: https://unicycive.com
Sector: Healthcare >> Biotechnology
Description: Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
